Horizon Pharma plc Form 3/A March 02, 2016

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

0.5

Estimated average burden hours per

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, response... Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *

A Beeler Brian K

(Last) (First) (Middle)

(Month/Day/Year)

05/06/2015

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

Horizon Pharma plc [HZNP]

C/O HORIZON PHARMA PLC, Â CONNAUGHT HOUSE,

1ST FL, 1 BURLINGTON RD

(Street)

Statement

4. Relationship of Reporting

Person(s) to Issuer

5. If Amendment, Date Original

Filed(Month/Day/Year)

05/08/2015

(Check all applicable)

Director _X__ Officer 10% Owner

Other (give title below) (specify below) EVP, General Counsel

6. Individual or Joint/Group

Filing(Check Applicable Line) _X_ Form filed by One Reporting

Person

Form filed by More than One

Reporting Person

4. Nature of Indirect Beneficial

DUBLIN, L2Â 4

(City) (State)

(Instr. 4)

1. Title of Security

(Zip)

2. Amount of Securities Beneficially Owned

(Instr. 4)

3. Ownership

> (I) (Instr. 5)

Table I - Non-Derivative Securities Beneficially Owned

Ownership (Instr. 5)

Â

Form: Direct (D)

or Indirect

D

Ordinary Shares $19,377 \frac{(1)}{2}$

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

> Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a

currently valid OMB control number.

SEC 1473 (7-02)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

Expiration Date (Month/Day/Year)

2. Date Exercisable and 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)

4. Conversion or Exercise

5. Ownership Form of Derivative

6. Nature of Indirect Beneficial Ownership

(Instr. 5)

Price of Derivative Security:

Edgar Filing: Horizon Pharma plc - Form 3/A

Date **Expiration Title** Exercisable Date

Amount or Security Number of Shares

Director 10% Owner Officer

Direct (D) or Indirect (I) (Instr. 5)

Reporting Owners

Reporting Owner Name / Address

Relationships

Other

Beeler Brian K

C/O HORIZON PHARMA PLC

CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD DUBLIN, L2Â 4

Â

Â EVP, General Counsel Â

Signatures

/s/ Miles W. McHugh, Attorney-in-Fact

03/02/2016

**Signature of Reporting Person

Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- 4,134 ordinary shares were inadvertently omitted from the reporting person's original Form 3, and also from one Form 4 filed by the reporting person after his original Form 3 was filed.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2